Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Definiens Expands Functionality of its Leading Solution for Quantitative Digital Pathology

Published: Monday, October 22, 2012
Last Updated: Monday, October 22, 2012
Bookmark and Share
Definiens Tissue Studio now supports the detection of spot-like signals from in situ hybridization assays.

Definiens® has announced that Definiens Tissue Studio® 3.5 now supports the automated analysis of in situ hybridization assays, including SISH, CISH, FISH and dual-ISH.

The unique combination of flexibility and ease-of-use that characterizes Definiens Tissue Studio® significantly facilitates the detection of spot-like signals originating from gene probes (or any other stain with spot-like appearance) on a cell-by-cell basis.

Definiens Tissue Studio® supports the detection of gene probe signals in both brightfield and immunofluorescene imaging.

The novel functionality complements the robust detection of regions of interest and the comprehensive quantification of cellular parameters and biomarker expression profiles.

Definiens Tissue Studio® can be used to analyze images from any solid tissue with any stain, acquired by any scanner or microscope, and in any common file format.

With these technological advances, pathologists and researchers can adapt preconfigured solutions to their specific assays with just a few clicks in no more than 30 minutes.

Straightforward workflow, intuitive configuration, as well as flexibility and robustness, have established Definiens Tissue Studio as the leading image analysis solution for quantitative digital pathology.

Definiens Tissue Studio opens new dimensions in quantification by significantly reducing study times in translational research, preclinical safety, tissue-based biomarker development and clinical trials around the world.

The new version includes a range of improvements that make it easier to use and more powerful than ever.

“Definiens has developed significant experience in the analysis of in situ hybridization assays in recent years,” said Thomas Heydler, CEO of Definiens.

Heydler continued, “In Definiens Tissue Studio® 3.5, we now make this available to our customers in a very easy-to-use workflow that supports virtually any type of 2D ISH assay. This further strengthens Definiens Tissue Studio’s position as the most comprehensive software package for quantitative digital pathology.”

With just a single configuration, Definiens Tissue Studio® automates the detection of regions of interest and has the capacity to distinguish individual cells and subcellular structures even in heterogeneous tissues samples.

The software provides quantitative readouts on morphological characteristics and molecular expression profiles of nuclear, cytoplasmic and membrane biomarkers.

In addition, Definiens Tissue Studio® supports robust detection of vessels for automated angiogenesis assays as well as extensive multiplexing for the quantification of numerous parameters from the same tissue sample in immunofluorescence assays.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Definiens Secures € 15 Million for Tissue Phenomics-based Cancer Diagnostics
Big data approach bridges the gap between genomics and personalized medicine.
Saturday, June 28, 2014
Definiens Expands Management Team to Develop the Clinical Market
Company announces appointment of Pablo Jordan and Rebecca Berghorn.
Tuesday, October 29, 2013
Definiens Appoints Chief Marketing Officer, Merrilyn Datta, Ph.D.
Dr. Datta brings a wealth of experience in marketing and her expertise will be critical as Definiens expands its leadership in the life sciences and tissue diagnostics industries.
Tuesday, April 09, 2013
Definiens Establishes Advisory Board
Renowned industry experts to advise Definiens on clinical digital pathology market.
Thursday, March 28, 2013
Definiens Strengthens Leadership with Key Appointment
Former Aperio executive and digital pathology market expert, Dr. Martin Stuart, joins executive team.
Thursday, February 02, 2012
Definiens Image Analysis Technology Improves Accuracy in Scoring Her2/neu in Breast Cancer Biopsies
New multi-dimensional image analysis platform aids diagnosis and treatment of breast cancer.
Wednesday, June 03, 2009
Scientific News
New Autism Blood Biomarker Identified
Researchers at UT Southwestern Medical Center have identified a blood biomarker that may aid in earlier diagnosis of children with autism spectrum disorder, or ASD.
Faster, Cheaper Way to Produce New Antibiotics
A novel way of synthesising a promising new antibiotic has been identified by scientists at the University of Bristol.
Monovar Drills Down Into Cancer Genome
Rice, MD Anderson develop program to ID mutations in single cancer cells.
Autism, Cancer Share a Remarkable Number of Risk Genes
Researchers with the UC Davis Comprehensive Cancer Center, MIND Institute identify more than 40 common genes.
Number Of Known Genetic Risk Factors For Endometrial Cancer Doubled
An international collaboration of researchers has identified five new gene regions that increase a woman’s risk of developing endometrial cancer, one of the most common cancers to affect women, taking the number of known gene regions associated with the disease to nine.
FNIH Launches Project to Evaluate Biomarkers in Cancer Patients
Company has announced that it has launched a new project to evaluate the effectiveness of liquid biopsies as biomarkers in colorectal cancer patients.
Genetic Risk Factors of Disparate Diseases Share Similar Biological Underpinnings
Penn Institute for Biomedical Informatics and colleagues identify "roadmap" of disease mechanisms to identify candidate drug targets.
Childhood Asthma Research Receives $2M
Research into the impact of a child’s upbringing and social and physical environments on the development of asthma will receive $2 million to tackle the condition that affects as many as one in three Canadians.
Making Precision Medicine a Reality
Researchers are one step closer to understanding the genetic and biological basis of diseases like cancer, diabetes, Alzheimer’s and rheumatoid arthritis – and identifying new drug targets and therapies.
Genetic Markers Influence Addiction
Differences in vulnerability to cocaine addiction and relapse linked to both inherited traits and epigenetics, U-M researchers find.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!